
A clinical trial starting on Nov. 19 at UC San Francisco could lead to the first precision medicines for a rapidly progressing, life-threatening breathing disorder.
The disorder, acute respiratory distress syndrome (ARDS), affects 1 in 10 patients in intensive care units (ICUs) and usually follows pneumonia, severe infection, or accident-related trauma. ARDS causes inflammation and fluid buildup in the lungs, making it difficult for oxygen to enter the bloodstream.
Currently, treatment for ARDS largely consists of supportive care, including mechanical ventilation, which delivers air enriched with oxygen into the lungs and can be lifesaving but may also worsen lung injury. For 35% to 45% of patients, ARDS is fatal.
Can a patient walk independently? Are they able to return to work?
MIChael Matthay, MD, professor of medicine and anesthesia at UCSF
The PANTHER trial is funded by the U.S. Department of Defense and will run at 10 institutions nationwide. Additional sites will be located abroad. The study builds on years of research by Carolyn Calfee, MD, and Michael Matthay, MD, professors of medicine and anesthesia at UCSF and co-directors of the Center for Precision Research in Critical Care, a new center dedicated to improving patient outcomes in the ICU through implementation of precision medicine.
Their research has identified two biological forms of ARDS, hyperinflammatory and the less inflamed hypo-inflammatory, raising the possibility that precision medicine for each could lead to better outcomes.
“We found that some treatments that appeared to improve survival in one form showed no benefit when patients with both forms were analysed together,” said Calfee, co-principal investigator of the UCSF site and one of the leads of the global PANTHER trial.
Researchers plan to enroll 300 patients at the U.S. sites.
Patients will first receive a blood test for biomarkers that classify them as having hyperinflammatory or hypo-inflammatory ARDS. One-third will be randomly assigned to receive usual care, which may include lung-protective mechanical ventilation, positioning patients on their stomachs to improve oxygen levels, and managing fluids to reduce fluid buildup in the lungs.
The remaining patients will receive usual care plus one of two drugs. The first, simvastatin, is widely used to lower cholesterol and also has broad anti-inflammatory effects; while baricitinib, which targets specific inflammatory pathways and is approved to treat rheumatoid arthritis, has shown some benefit in treating ARDS resulting from severe COVID-19.
PANTHER is an adaptive trial platform that enables the study to change as evidence accumulates. Promising new drugs can be added, while drugs that are shown to be ineffective will be dropped.
The study will measure survival and the number of days during the first 28 days that patients live without major life support treatments, such as mechanical ventilation or drugs to maintain blood pressure.
“Additionally, we will be looking at the extent to which a patient can recover,” said Matthay, co-principal investigator of the UCSF site and a member of PANTHER’s biobanking team, which collects blood samples. “Can a patient walk independently? Are they able to return to work? Are they recovering their cognitive skills, and do they have the muscle strength to perform everyday tasks?”
Many people who survive ARDS face long-term cognitive impairment and significant physical limitations, according to the National Heart, Lung, and Blood Institute.